Johnson & Johnson $JNJ Shares Bought by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 8.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 63,813 shares of the company’s stock after purchasing an additional 4,916 shares during the period. Johnson & Johnson accounts for about 0.7% of Meeder Advisory Services Inc.’s portfolio, making the stock its 27th biggest position. Meeder Advisory Services Inc.’s holdings in Johnson & Johnson were worth $15,598,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in JNJ. Scarborough Advisors LLC purchased a new stake in Johnson & Johnson in the first quarter valued at about $241,000. Parallel Advisors LLC lifted its position in Johnson & Johnson by 1.2% during the 1st quarter. Parallel Advisors LLC now owns 80,406 shares of the company’s stock worth $19,655,000 after acquiring an additional 966 shares during the period. Resolute Wealth Strategies LLC grew its stake in Johnson & Johnson by 6.1% during the 1st quarter. Resolute Wealth Strategies LLC now owns 2,778 shares of the company’s stock valued at $679,000 after purchasing an additional 159 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at about $320,000. Finally, Planning Alternatives Ltd. ADV raised its stake in shares of Johnson & Johnson by 66.9% in the first quarter. Planning Alternatives Ltd. ADV now owns 3,419 shares of the company’s stock worth $836,000 after purchasing an additional 1,371 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 1.7%

Shares of JNJ stock opened at $248.83 on Tuesday. Johnson & Johnson has a twelve month low of $162.78 and a twelve month high of $269.43. The stock has a market cap of $598.99 billion, a P/E ratio of 28.83, a P/E/G ratio of 2.39 and a beta of 0.24. The stock has a 50 day moving average of $240.37 and a 200 day moving average of $235.11. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The business’s revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.68 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Bank of America increased their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. Raymond James Financial upped their price objective on shares of Johnson & Johnson from $258.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday. Johnson Rice upgraded shares of Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 price objective on the stock in a research note on Thursday. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Finally, Scotiabank restated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.30.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J’s robust Q2 performance beat estimates for both earnings and revenue, prompting the company to raise its 2026 outlook and reinforcing confidence in its core pharmaceuticals and MedTech businesses. Article: Should You Buy, Sell or Hold J&J’s Stock Post a Robust Q2 Performance?
• Positive Sentiment: New MedTech developments, including an acquisition in spine technologies and FDA approval for a heart-device platform, add to J&J’s growth story and expand its medical device portfolio. Article: Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device
• Positive Sentiment: Several articles framed J&J as a long-term defensive holding, citing its diversified healthcare footprint, AAA-like balance sheet strength, and 64-year dividend growth streak, which can support investor demand during market volatility. Article: Why Johnson & Johnson Is a Stock You Can Own Forever

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.